XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue - Disaggregation of Revenue by Product (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenue $ 11,439.1 $ 9,498.6 $ 31,509.9 $ 24,770.7
U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 7,813.6 5,368.1 21,343.2 15,335.6
Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 3,625.5 4,130.5 10,166.7 9,435.0
Cardiometabolic Health        
Disaggregation of Revenue [Line Items]        
Revenue 7,407.0 4,720.4 20,414.6 13,921.6
Cardiometabolic Health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 5,517.0 3,460.0 15,323.0 10,316.4
Cardiometabolic Health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,890.0 1,260.3 5,091.6 3,605.2
Mounjaro®        
Disaggregation of Revenue [Line Items]        
Revenue 3,112.7 1,409.3 8,010.0 2,957.5
Mounjaro® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 2,384.7 1,277.0 6,318.7 2,729.1
Mounjaro® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 728.0 132.4 1,691.3 228.4
Trulicity®        
Disaggregation of Revenue [Line Items]        
Revenue 1,301.4 1,673.6 4,003.3 5,463.2
Trulicity® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 935.3 1,259.0 2,894.0 4,177.7
Trulicity® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 366.0 414.6 1,109.3 1,285.6
Zepbound®        
Disaggregation of Revenue [Line Items]        
Revenue 1,257.8 0.0 3,018.4 0.0
Zepbound® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,257.8 0.0 3,018.4 0.0
Zepbound® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 0.0 0.0 0.0 0.0
Jardiance        
Disaggregation of Revenue [Line Items]        
Revenue 686.4 700.8 2,142.5 1,946.6
Jardiance | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 335.9 415.9 1,133.1 1,131.5
Jardiance | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 350.5 284.8 1,009.4 815.1
Humalog®        
Disaggregation of Revenue [Line Items]        
Revenue 534.6 395.4 1,704.9 1,296.8
Humalog® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 323.9 194.2 1,096.8 695.6
Humalog® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 210.8 201.2 608.1 601.2
Humulin®        
Disaggregation of Revenue [Line Items]        
Revenue 207.1 206.7 636.8 664.0
Humulin® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 149.9 145.5 472.3 488.6
Humulin® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 57.1 61.2 164.5 175.4
Basaglar®        
Disaggregation of Revenue [Line Items]        
Revenue 161.6 179.6 500.0 543.1
Basaglar® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 85.5 111.4 273.9 329.7
Basaglar® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 76.2 68.2 226.1 213.4
Baqsimi        
Disaggregation of Revenue [Line Items]        
Revenue 13.4 13.1 24.8 658.4
Baqsimi | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 8.2 3.8 1.4 633.1
Baqsimi | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 5.1 9.3 23.4 25.4
Other cardiometabolic health        
Disaggregation of Revenue [Line Items]        
Revenue 132.0 141.9 373.9 392.0
Other cardiometabolic health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 35.8 53.2 114.4 131.1
Other cardiometabolic health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 96.3 88.6 259.5 260.7
Oncology        
Disaggregation of Revenue [Line Items]        
Revenue 2,231.8 1,747.1 6,200.5 4,774.1
Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,294.3 1,001.6 3,567.9 2,690.0
Oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 937.5 745.5 2,632.6 2,084.1
Verzenio®        
Disaggregation of Revenue [Line Items]        
Revenue 1,369.3 1,040.2 3,751.5 2,717.9
Verzenio® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 878.8 684.6 2,378.4 1,734.2
Verzenio® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 490.4 355.7 1,373.1 983.7
Cyramza®        
Disaggregation of Revenue [Line Items]        
Revenue 236.0 224.1 714.7 721.1
Cyramza® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 106.5 88.0 329.9 303.6
Cyramza® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 129.4 136.1 384.8 417.5
Erbitux®        
Disaggregation of Revenue [Line Items]        
Revenue 152.0 153.9 452.4 446.3
Erbitux® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 133.2 134.0 408.2 398.3
Erbitux® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 18.7 19.9 44.2 48.0
Tyvyt®        
Disaggregation of Revenue [Line Items]        
Revenue 150.2 115.1 389.9 279.7
Tyvyt® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 0.0 0.0 0.0 0.0
Tyvyt® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 150.2 115.1 389.9 279.7
Other oncology        
Disaggregation of Revenue [Line Items]        
Revenue 324.3 213.8 892.0 609.1
Other oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 175.8 95.0 451.4 253.9
Other oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 148.8 118.7 440.6 355.2
Immunology        
Disaggregation of Revenue [Line Items]        
Revenue 1,185.7 986.9 3,102.0 2,693.2
Immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 694.1 575.0 1,691.0 1,452.6
Immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 491.6 412.0 1,411.0 1,240.6
Taltz®        
Disaggregation of Revenue [Line Items]        
Revenue 879.6 744.2 2,308.4 1,975.0
Taltz® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 600.3 509.3 1,486.7 1,293.8
Taltz® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 279.3 234.9 821.7 681.2
Olumiant®        
Disaggregation of Revenue [Line Items]        
Revenue 250.8 231.4 695.9 679.2
Olumiant® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 68.9 65.7 159.8 158.8
Olumiant® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 181.8 165.7 536.0 520.4
Other immunology        
Disaggregation of Revenue [Line Items]        
Revenue 55.3 11.4 97.7 39.0
Other immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 24.9 0.0 44.5 0.0
Other immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 30.5 11.4 53.3 39.0
Neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 351.8 1,768.1 1,080.4 2,515.8
Neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 201.3 207.4 556.4 512.8
Neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 150.5 1,560.6 524.0 2,003.0
Emgality®        
Disaggregation of Revenue [Line Items]        
Revenue 202.9 168.5 620.6 492.2
Emgality® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 141.3 126.5 404.0 354.0
Emgality® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 61.6 42.1 216.7 138.2
Zyprexa        
Disaggregation of Revenue [Line Items]        
Revenue 31.7 1,481.4 107.5 1,651.0
Zyprexa | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1.9 49.9 0.5 69.1
Zyprexa | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 29.8 1,431.5 107.0 1,581.9
Other neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 117.2 118.2 352.3 372.6
Other neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 58.1 31.0 151.9 89.7
Other neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 59.1 87.0 200.3 282.9
Other        
Disaggregation of Revenue [Line Items]        
Revenue 262.8 276.1 712.4 866.0
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 107.0 124.1 205.0 363.8
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 155.8 152.0 507.4 502.1
Forteo®        
Disaggregation of Revenue [Line Items]        
Revenue 118.1 146.4 249.3 416.8
Forteo® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 71.7 101.2 124.9 269.2
Forteo® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 46.4 45.2 124.4 147.6
Cialis®        
Disaggregation of Revenue [Line Items]        
Revenue 91.5 86.8 318.6 302.7
Cialis® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 4.2 4.9 17.6 21.6
Cialis® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 87.3 82.0 301.0 281.1
Other        
Disaggregation of Revenue [Line Items]        
Revenue 53.2 42.9 144.5 146.5
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 31.1 18.0 62.5 73.0
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue $ 22.1 $ 24.8 $ 82.0 $ 73.4